Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose,
placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550
mg) in the acute treatment of migraine.